Although molecular biomarkers such as isocitrate dehydrogenase (IDH) mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status, aid in the precise stratification of GBM survival [8], current methods for obtaining such information are always invasive, costly, and vulnerable to sampling errors resulting from GBM’s high heterogeneity. The gene discussed is MGMT; the disease is glioblastoma.